Status:
UNKNOWN
Low-dose Ticagrelor in Chinese ACS Patients Undergoing PCI
Lead Sponsor:
First Affiliated Hospital of Harbin Medical University
Conditions:
Acute Coronary Syndrome
Eligibility:
All Genders
18-75 years
Phase:
PHASE4
Brief Summary
Dual Antiplatelet Therapy (DAPT) with aspirin and P2Y12 receptor inhibitor remains a cornerstone in the secondary prevention of coronary artery disease (CAD). Clopidogrel is one of the most commonly u...
Eligibility Criteria
Inclusion
- After half-dose ticagrelor (loading dose 90mg, and then 45mg bidpo.) treatment for 3 days, the platelet aggregation is effectively inhibited by light transmission aggregometry method and thromboela-stogram.
- planned to undergo PCI recently
- planned to DAPT for 1 year after PCI
Exclusion
- taken adenosine diphosphate (ADP) receptor antagonists within 2 weeks
- Platelet count \<100g/L;
- A history of bleeding tendency;
- Aspirin, ticagrelor or clopidogrel allergies;
- Severe liver injury.
Key Trial Info
Start Date :
January 1 2018
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 14 2020
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT03381755
Start Date
January 1 2018
End Date
December 14 2020
Last Update
September 12 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Thromboela-Stogram
Beijing, Beijing Municipality, China, 100001